Sagimet Biosciences (STU:0O2) Debt-to-Equity: 0.00 (As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Debt-to-Equity?

Sagimet Biosciences STU:0O2 +1.66% 10 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Sagimet Biosciences ranks worse than 103626.84% on this metric.

Sagimet Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0.03 Mil. Sagimet Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0.00 Mil. Sagimet Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €88.63 Mil. Sagimet Biosciences's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sagimet Biosciences's Debt-to-Equity or its related term are showing as below:

STU:0O2's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Sagimet Biosciences  (STU:0O2) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sagimet Biosciences Debt-to-Equity Related Terms

Sagimet Biosciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Debt-to-Equity Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial -0.00 -0.00 0.00 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0O2 vs EDIT, AUTL, FBRX: Debt-to-Equity Comparison

For the Biotechnology subindustry, Sagimet Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Debt-to-Equity falls into.


STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sagimet Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.067 + 0) / 95.119
=0.00

Sagimet Biosciences's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.034 + 0) / 88.626
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Sagimet Biosciences (STU:0O2) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #999999 out of 965 companies in the Biotechnology industry.
Is Sagimet Biosciences' Debt-to-Equity too high?
Sagimet Biosciences' current Debt-to-Equity is 0.00. Based on the distribution chart, Sagimet Biosciences ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Debt-to-Equity compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #999999 out of 965 companies for Debt-to-Equity. This places Sagimet Biosciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price